CAPT Jonathan Forsberg, M.D., Ph.D., is leading a new study to investigate the use of next-generation osseointegrated devices.

HJF received one million dollars to fund a study investigating 4-aminopyrydine (4-AP) as a TBI treatment.

In research presented virtually at IDWeek 2021, investigators found that cardiovascular disease (CVD) diagnoses, in particular, remained elevated for 3 months.

HJF donated military first aid kits to the San Antonio and Austin police departments.

September is Prostate Disease Awareness Month.

Meet the two recipients of the 2021 HJF fellowship award.

HJF was awarded a contract for overseas support activities for U.S. Army Medical Research Directorate-Africa.

Patented technology uses extracts from the worm, Caenorhabditis elegans, to treat autoimmune diseases and allergies.

AI can predict the status of three important biomarkers from routine breast cancer.

HJF co-hosted a day of virtual COVID-19 research presentations in collaboration with DoD partners.

A recently released study shows that colon cancer patients in the Military Health System have significantly better survival, compared to general population.

The Washington Business Journal identified HJF as the second largest biosciences employer in the greater Washington D.C. metro area.

HJF received notice of allowance for a patent for a medical countermeasure to organophosphate (OP) exposure, including the deadly chemical weapon Sarin.

This year's Heroes of Military Medicine Honorees all contributed to the fight against COVID-19. Learn more in this article by HJF writer Dave Savold.

This DOD-funded initiative will assess the role of continuous biosensor data and artificial intelligence in addressing the COVID-19 pandemic.